Effects of Vaping on Post-operative Recurrence of Crohn's Disease: a Retrospective Multicenter Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Tobacco smoke is a well-established risk factor for post-operative recurrence of Crohn's disease. Over the last few decades electronic cigarettes have gained popularity as an alternative to traditional tobacco, however, their effects on Crohn's disease are unknown. Tobacco smoke negatively impacts most outcomes of Crohn's disease including, but not limited to, response to therapy and risk of hospitalization. Smoke is particularly relevant in the post-operative setting, as it increases the chance of disease recurrence after surgical resection, and therefore prophylactic treatment with biologics is recommended in Crohn's patients who smoke. At present, there are no studies evaluating the impact of e-cigarette smoke on post-operative recurrence and therefore informing physicians on the appropriateness of prophylactic treatment in this subset of patients. This study aims to assess the impact of vaping (or smoking of electronic cigarettes) on Crohn's disease endoscopic recurrence after resection as compared to non-smoke and smoke of traditional tobacco cigarettes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult (age ≥18) patients with an established diagnosis of Crohn's disease.- Patients who underwent surgical resections of a tract of intestine accessible through endoscopy.

• Patients who underwent ileo-colic resections due to Crohn's disease or its complications (stricture or fistula) irrespective of the type of anastomosis (side-to-side L-L, , end-to-end T-T, end-to-side T-L, Kono S, iso or antiperistaltic)

• Patients whose smoking habit (or nonsmoking habit) is clearly reported in the medical records

• Data will be collected from January 2000 to August 2024.

Locations
Other Locations
Italy
IRCCS San Raffaele
RECRUITING
Milan
Contact Information
Primary
Tommaso Lo Parigi, MD
parigi.tommaso@hsr.it
02 2643 2756
Time Frame
Start Date: 2024-11-30
Estimated Completion Date: 2025-08
Participants
Target number of participants: 600
Treatments
Adult patients (age ≥18) diagnosed with CD
Patients who underwent intestinal resections due to Crohn's disease or its complications
Related Therapeutic Areas
Sponsors
Leads: IRCCS Ospedale San Raffaele

This content was sourced from clinicaltrials.gov